CyberKnife procedures enjoy robust growth
The utilization of radiotherapy device developer Accuray’s CyberKnife robotic radiosurgery system has increased by 75 percent worldwide during the company’s 2007 fiscal year (end-June 30), according to the Sunnyvale, Calif.-based firm.
The highest growth in use of the technology was seen in the treatment of lung and prostate cancer in the United States, which doubled and quadrupled respectively since the end of fiscal year 2006, Accuray said.
More than 95 percent of CyberKnife facilities in the United States treat lung cancer. Furthermore, lung cancer patients accounted for 18 percent of all United States. CyberKnife treatments during fiscal year 2007, while prostate cancer treatments with the CyberKnife system showed a 320 percent growth rate in the United States over the last fiscal year, the company reported.
Accuray said that patients treated by the CyberKnife system in the United States for liver and pancreas tumors increased by 74 percent and 56 percent respectively. In addition, the number of patients undergoing CyberKnife treatments for spinal tumors in the United States increased 37 percent.
The highest growth in use of the technology was seen in the treatment of lung and prostate cancer in the United States, which doubled and quadrupled respectively since the end of fiscal year 2006, Accuray said.
More than 95 percent of CyberKnife facilities in the United States treat lung cancer. Furthermore, lung cancer patients accounted for 18 percent of all United States. CyberKnife treatments during fiscal year 2007, while prostate cancer treatments with the CyberKnife system showed a 320 percent growth rate in the United States over the last fiscal year, the company reported.
Accuray said that patients treated by the CyberKnife system in the United States for liver and pancreas tumors increased by 74 percent and 56 percent respectively. In addition, the number of patients undergoing CyberKnife treatments for spinal tumors in the United States increased 37 percent.